On May 3, 2019, the FDA approved Kadcyla to treat early-stage HER2-positive breast cancer after surgery if there were cancer cells found during surgery after neoadjuvant chemotherapy with a taxane and Herceptin.
Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy.
An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women.
A fixed-dose combination of Herceptin and Perjeta given as an injection in the thigh along with chemotherapy before surgery seems to offer the same benefits as IV infusions of the two medicines for people diagnosed with early-stage HER2-positive breast cancer.
Nearly all the people in a clinical trial who were receiving systemic intravenous cancer treatment had an adequate immune response to the Pfizer-BioNTech COVID-19 vaccine.
Women diagnosed with early-stage, HER2-positive breast cancer treated with both Herceptin and Tykerb after surgery had the same disease-free survival as women treated with only Herceptin after surgery.
On Sept. 13, 2019, the FDA released a statement warning about a link between rare but severe lung inflammation and the three CDK4/6 inhibitors used to treat advanced-stage hormone-receptor-positive, HER2-negative breast cancer.
A small study suggests that heart medicines, such as beta blockers or ACE inhibitors, taken along with Herceptin can reduce the risk of serious heart damage in women diagnosed with early-stage, HER2-positive breast cancer.
Adding Afinitor to Faslodex offers benefits when treating metastatic, hormone-receptor-positive, HER2-negative breast cancer that has become resistant to aromatase inhibitors.
Latest results from MONARCH 2 study show adding Verzenio to Faslodex improves overall survival by 9 months for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.
On April 22, 2020, the FDA granted accelerated approval to Trodelvy to treat adults diagnosed with metastatic triple-negative breast cancer who have received at least two previous treatments for metastatic disease.
Experimental alpelisib combined with Faslodex improved progression-free survival more than Faslodex alone in people diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Nerlynx was approved by the FDA on July 17, 2017 to treat early-stage, HER2-positive breast cancer for an extended period after surgery in people who have previously been treated with Herceptin.
Kisqali along with either an aromatase inhibitor or tamoxifen and medicine to suppress ovarian function offers better progression-free survival than just hormonal therapy and ovarian suppression in premenopausal women with advanced-stage, hormone-receptor-positive, HER2-negative disease.
Avastin combined with Taxol lengthens the time until advanced breast cancer progresses, but doesn't improve overall survival.
The FDA has recommended removing the breast cancer indication from Avastin because the medicine has not been shown to be safe and effective for that use.
A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.
A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.
Newer chemotherapy medicines and regimens, as well as targeted therapy medicines, are helping women with advanced-stage breast cancer live longer.
The FDA is considering whether to continue the approval for using Avastin with Taxol to treat metastatic breast cancer, as well as whether to approve it in combination with other medicines.
The FDA has decided to not consider accelerated approval for T-DM1 to treat HER2-positive, advanced-stage breast cancer based on research results available as of August 2010.
A small study suggests that older women diagnosed with HER2-positive, metastatic breast cancer can benefit from Herceptin treatment.
Research shows that adding Avastin to neoadjuvant chemotherapy doesn't seem to benefit women diagnosed with early-stage or locally-advanced breast cancer.
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.